Page 3 - முழங்கால் ஆஸ்டியோவார்த்ரைடிஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

nd generation novel bi-specific CAR-T therapy targeting both CD19 and CD20 antigens Indications: Relapsed/refractory B-cell non-Hodgkin s lymphoma (B-NHL) C-CAR039 has been developed as a novel 2nd generation 4-1BB bi-specific CAR-T targeting both CD19 and CD20 antigens with an optimized bi-specific antigen binding domain. C-CAR039 can eradicate CD19/CD20 single or double positive tumor cells  in vitro and  invivo. The tissue cross reactivity and whole genome membrane proteome array studies further confirmed the specificity of C-CAR039. C-CAR039 demonstrated a favorable safety profile and promising efficacy in this early clinical trial in patients with r/r B-NHL that might allow it to differentiate from existing therapies. The early clinical efficacy signal is encouraging and compares favorably to anti-CD19 CAR-T and peer therapies. These findings will be evaluated in more patients with longer follow-up to confirm safety, efficacy and duration of response. Clinical trial in

United statesSarah kellyCommunications investor relationsAmerican society of clinical oncologyCompany contactLaboratory of cell therapyApplication centerCell therapy technology innovationGe healthcareClinical oncologyAnnual meetingDevelopmental therapeuticsThermo fisherKnee osteoarthritisInvestor relationsCbmg holdings